Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

6.70$-0.30 -4.29 %
At close       04:00 PM    

Stock Snapshot

7.00
Prev. Close
6.90
Open
529.36M
Market Cap
8520.00
Number of Shares
6.56
Day Low
7.13
Day High
6.70
-
P/E Ratio
-
Free Float in %
-1.15
EPS 2021
-
Book Value per Share
-
Cash Flow per Share
Innate Pharma S.A. (IPHA)
Innate Pharma S.A. (IPHA) stock rallied over -4.29% intraday to trade at $6.70 share on NASDAQ. The stock opened with a fall of % at $6.90 and touched an intraday high of $7.13, rising 1.86% against the last close of $7.00. The stock went to a low of $6.56 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$6.44$6.02$6.44$5.92616,865
2021-09-03$4.48$6.15$8.90$4.024,059,640,000
2021-09-02$5.23$4.18$5.62$3.712,272,740,000
2021-09-01$3.68$3.62$3.68$3.624,700,000
2021-08-31$3.70$3.64$3.70$3.602,050,000
2021-08-30$3.58$3.57$3.58$3.54300,000
2021-08-27$3.54$3.53$3.63$3.52220,000
2021-08-26$3.40$3.38$3.54$3.38890,000
2021-08-25$3.35$3.37$3.37$3.33800,000
2021-08-24$3.33$3.37$3.37$3.3380,000
2021-08-23$3.36$3.40$3.40$3.36340,000
Innate Pharma S.A.
117 Avenue de Luminy
BP 30191
Marseille 13009
France

http://www.innate-pharma.com
33 4 30 30 30 30
Employees
-
Sector
Healthcare
Sales or Revenue
70.45M
Industry
Biotechnology
5Y Sales Change
-
Fiscal Year Ends
2020-12-30

Innate Pharma S.A.
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam